Neuroimaging  Pathognomonic  Manifestations Of  Cerebral  Amyloid  Angiopathy

Yu. Severyn V. N. Karazin Kharkiv National University

Abstract

The article concerns the problem of cerebral amyloid angiopathy (CAA), a chronic progressive disease of the brain vessels, characterized by the deposition of β-amyloid peptide in the walls of arteries, arterioles, capillaries and venules. The data on etiology, pathogenesis, clinical manifestations, diagnosis and treatment of the disease are given. Particular attention to the neuroimaging diagnostics, that allow to identify the disease at an early stage with a non-invasive method is paid. Radial diagnostic criteria of CAA, which are prognostically important for diagnosis, evaluation of the course and prognosis of the disease are obtained.

Downloads

Download data is not yet available.

References

Boyle P.A., Yu L., Nag S., Leurgans S. [et al.] Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology, 2015, vol. 85, no. 22, pp. 1930-6.

Reijmer Y. D., Fotiadis P., Martinez-Ramirez S. [et al.] Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain, 2015, vol. 138, pt. 1, pp. 179-88.

Case N. F., Charlton A., Zwiers A., [et al.] Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment. Stroke, 2016, STROKEAHA.116.012999 published online before print June 23 2016.

Fateeva V., Nemenova E., Vorobjova O. Cerebral’naja angiopatija kak prichina spontannuh recidivirujuschih krovoizlijanij v mozg. [Cerebral amyloid angiopathy as a cause of recurrent spontaneous hemorrhages into the brain]. Vrach, 2013, vol. 5, pp. 40–43 (In Russ.)

Kummer M. P., Heneka M. T. Truncated and modified amyloid-beta species. Alzheimer’s Research & Therapy, 2014, vol. 6, pp. 28.

Musiek E. S., Holtzman D. M. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nature Neuroscience, 2015, vol. 18, pp. 800-806.

Levin O. S. Diagnostica i lechenie dementsii v klinicheskoj praktike [Diagnosis and treatment of dementia in clinical practice]. MEDpress-inform, 3rd ed, 2012, pp. 256. (In Russ.)

Price D. L., Tanzi R. E., Borchelt D. R., Siso dia S. S. Alzheimer’s disease:genetic studies and transgenic models. Annu Rev Genet, 1998, vol. 32, pp. 461–493.

Schellenberg G. D., Montine T. J. The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol, 2012, vol.124, no. 3, pp. 305–323.

Frontzek K., Lutz M. I., Aguzzi A., et al. Amy-loid-β pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly, 2016, vol. 146: w14287. Published online 2016 January 26. doi: 10.4414/smw.2016.14287

Jucker M., Walker L. C. Neurodegeneration: Amyloid-β pathology induced in humans. Nature, 2015, vol. 525, no. 7568, pp. 193–194.

Jaunmuktane Z., Mead S., Ellis M. [et al.] Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature, 2015, vol. 525, no. 7568, pp. 247–250.

Makotrova T. A., Levin O., Arablinsky A. V. Cerebral’naja amiloidnaja angiopatija [Cerebral amyloid angiopathy]. Journal of Neurology and Psychiatry im. S. S. Korsakova, 2014, vol. 114, no Ap. to No 6 (Issue 2. Neurology and Psychiatry elderly), pp. 87-93.

Vinters H. V. Cerebral amyloid angiopathy: a critical review. Stroke, 1987, vol. 18, pp. 311–324.

Salvarani C., Hunder G. G., Morris J. M. [et al.] Aβ-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology, 2013, vol. 81, pp. 1596–1603.

Greenberg S. M. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology, 1998, vol. 51, no. 3, pp. 690-694.

Liu C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol., 2013, vol. 9, pp. 106-118.

Biffi A., Shulman J. M., Jagiella J. M. [et al.]Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology, 2012, vol. 78, pp. 334–341.

Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 9, 106-118 (2013)

Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke, 2015, vol. 17, pp. 17–30.

Ghiso J., Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. Journal of Alzheimer’s Disease, 2001, vol. 3, pp. 65–73.

Biffi A., Greenberg S. Cerebral Amyloid Angiopathy: A Systematic Review. The Journal of Clinical Neurology, 2011, vol. 7, pp. 1-9

Greenberg S. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology, 1998, vol. 51, pp. 690–694.

Auriel Е., Greenberg S. M. The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy. Curr Atheroscler Rep., 2012, vol. 4, pp. 343–350.

Kinnecom C. L., Wendell L.; Smith E. E. [et al.] Course of cerebral amyloid angiopathy–related inflammation. Neurology, 2007, vol. 68, no. 17, pp. 1411-1416.

Oh U., Gupta R., Krakauer J. W. [et al.] Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology, 2004, vol. 62, no. 3, рр. 494-497.

Revesz T., Ghiso J., Lashley T. [et al.] Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol, 2003, vol. 62, pp. 885–898.

Salvarani C., Brown R. D. Jr, Calamia K. T. 3rd [et al.] Angiography-negative primary central nervous system vasculitis: a syndrome involving small cerebral vessels. Medicine (Baltimore),2008, vol. 87, pp. 264–271.

Salvarani C., Morris J. M., Giannini C. [et al.] Imaging Findings of Cerebral Amyloid Angiopathy, Aβ-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy–Related Inflammation: A Single-Institution 25-Year Experience. Medicine, 2016, vol. 95, issue 20, pp. e3613.

Martucci M., Sarria S., Toledo M. [et al.] Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology, 2014, vol. 56, pp. 283–289.

Auriel E., Charidimou A, Gurol M. E. [et al.] Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation., 2016, vol. 73, no. 2, pp. 197-202.

Raghavan P., Looby S., Bourne T. D., Winter-mark M. Cerebral amyloid angiopathy-related inflammation: a potentially reversible cause of dementia with characteristic imaging findings. J Neuroradiol, 2016, vol. 43, no. 1, pp. 11-7.

Knudsen K. A., Rosand J., Karluk D., Greenberg S. M. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology, 2001, vol. 56, pp. 537–539.

Charidimou A., Gang Q., Werring D. J. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry, 2012, vol. 83, pp. 124–137.

Kloppenborg R.P., Richard E., Sprengers M. E. [et al.] Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J. Neuroinf lammation, 2010, vol. 7, pp. 8.

Arima H., Tzourio C., Anderson C. [et al.] Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke, 2010, vol. 41, no. 2, pp. 394-396.